德國醫(yī)學專家22日公布的一項研究結(jié)果表明,，在治療癌癥患者時使用熱療和化療相結(jié)合的方法比單一接受化療效果更好,，無瘤期更長。
實驗室研究發(fā)現(xiàn),，在針對肌肉,、脂肪、關節(jié)組織等軟組織實施熱療和化療時,，熱療促使癌細胞反應的比例是化療的兩倍,。更為重要的是，在結(jié)合熱療和化療過程中,，熱療不會增加化療的副作用,。
盡管仍需進一步證實，但專家說，熱療可輔助化療或有助于減少化療劑量,。
熱療法源于一種“區(qū)域高熱”技術,。治療時，可使電磁能量集中在患者腫瘤周圍組織,，使溫度升至40攝氏度至43攝氏度,。進行此項研究的德國慕尼黑大學腫瘤學教授羅爾夫·伊塞爾斯說，熱量不僅能殺死癌細胞,，似乎還能通過增強癌細胞的敏感性使化療取得更佳效果,。
伊塞爾斯說，接受熱療與化療相結(jié)合的軟組織惡性腫瘤患者,，“各項療效指標良好”,，“與單純接受化療相比，接受混合療法近3年后,，患者癌癥在同一部位復發(fā)的幾率降低42％,，患者死亡率也下降”。
兩組臨床患者試驗中,，單純接受化療患者的平均無瘤期為18個月,，而接受熱療與化療相結(jié)合患者的平均無瘤期為32個月，增加30％,。
伊塞爾斯說：“熱療與放射療法結(jié)合治療乳腺癌和宮頸癌的療效已經(jīng)顯現(xiàn)。用熱療輔助化療治療包括胰腺癌和直腸癌在內(nèi)的研究眼下已經(jīng)起步,。我們期待此項研究結(jié)果能被臨床應用于治療其他局部癌癥晚期患者,。”（生物谷Bioon.com）
生物谷推薦原始出處：
International Journal of Hyperthermia 2009, Vol. 25, No. 4, Pages 262-272
Combination of hyperthermia and bortezomib results in additive killing in mantle cell lymphoma cells
Valeria Milani, MD1,2, Monika Lorenz2, Valeria Milani, MD1,2, Monika Lorenz2, Marc Weinkauf3, Malte Rieken3, Alessandro Pastore1,3, Martin Dreyling1,3 and Rolf Issels1,2
1Department of Medical Oncology, University Medical Center Grosshadern, Munich, Germany
2CCG Hyperthermia, Helmholtz Zentrum München - H?matologikum, Munich, Germany
3AG Dreyling, Helmholtz Zentrum München - H?matologikum, Munich, Germany
The proteasome inhibitor bortezomib exhibits antitumor activity in many malignancies including mantle cell lymphoma (MCL). Unfortunately, many patients fail to respond to treatment or become refractory. Hyperthermia is an effective chemosensitizer that in combination with some chemotherapeutic agents has shown clinical activity in phase II and III studies. The aim of this study was to use MCL cell lines to investigate the potential benefit of combining clinically relevant doses of bortezomib with two different thermal doses (41.8°C/120 min and 44°C/30 min) that mimic the heterogeneity of the temperature distributions achieved within tumors during hyperthermia. Treated tumor cells were assessed for proliferation using the WST-1 assay and for apoptosis by annexin V staining, while heat shock protein (HSP) levels were determined following western blot analysis. Our results demonstrated that MCL cell lines that are sensitive to bortezomib are also thermosensitive and have low basal expression of hsp27, whereas the bortezomib-resistant MCL cell line strongly expresses hsp27 and is thermoresistant. Interestingly, pre-treatment of MCL cell lines with heat at the two different thermal doses, and the transient elevation of hsp27 and hsp70, do not impair their primary sensitivity to bortezomib. Finally, we show that the concurrent treatment of heat and bortezomib results in additive killing in MCL cell lines.In conclusion, these results suggest that the application of bortezomib, under thermal conditions, in mantle cell lymphoma cells may be beneficial and warrants further investigation.
